New recommendations for arterial hypertension management and blood pressure targets for type 2 diabetes mellitus

Česká verzia

Authors: Andrej Dukát; Peter Jackuliak; Juraj Payer
Authors place of work: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in the journal: Forum Diab 2024; 13(1): 23-26

Summary

Type 2 diabetes mellitus is a well-established cardiovascular risk factor. Its prevalence increases in all developed and developing countries and leads to the high current cardiovascular mortality. To these factors also hypertension accounts to this high attributable risk. Answer to the question about of treatment goals of blood pressure in type 2 diabetes mellitus were changing during the time. Randomized clinical trials lead to the publishing of the guidelines for the clinical practice. Last two years both diabetological and cardiological societies brought their guidelines for the treatment of hypertension in patients with type 2 diabetes mellitus in the current world.

Keywords:

hypertension – type 2 diabetes mellitus – blood pressure – treatment

Zdroje

Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension 2020; 75(2): 285–292. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14240>.

Kim HJ, Kim KI. Blood Pressure Target in Type 2 Diabetes mellitus. Diab Metab J 2022; 46(5): 667–674. Dostupné z DOI: <http://dx.doi.org/10.4093/dmj.2022.0215>.

[American Diabetes Association Professional Practice Committee]. 10. Cardiovascular disease and risk management: standards of medical care in diabetes 2022. Erratum in Erratum. Diabetes Care 2022; 45(5): 1296. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-er05>. Addendum. Diabetes Care 2022; 45(9): 2178–2181. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-ad08>.

Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.

NICE. Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE): London 2022: 47. Dostupné z WWW: <https://www.nice.org.uk/guidance/ng136>.

[UK Prospective Diabetes Study Group]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998: 317(7160): 703–713.

Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351(9118): 1755–1762. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(98)04311–6>.

Patel A, MacMahon S, Chalmers J et al. [ADVANCE Collaborative Group]. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370(9590): 829–840. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(07)61303–8>.

Cooper-DeHoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304(1): 61–68. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2010.884>.

[American College of Cardiology]. Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial – ACCORD BP. Dostupné z WWW: <https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2014/02/19/15/35/ACCORD-BP>.

Wright JT, Williamson JD, Whelton PK et al. [SPRINT Research Group]. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373(22): 2103–2116. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1511939>.

Buckley LF, Dixon DL, Wohlford GF et al. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care 2017; 40(12): 1733–1738. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–1366>. Erratum in Erratum. Diabetes Care 2018; 41(9): 2048. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18-er09>.

Emdin CA, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313(6): 603–615. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.18574>.

Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352: i717. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.i717>.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on outcome incidence in hypertension. 10. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017; 35(5): 922–944. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000001276>.

Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertension 2023; 41(12): 1874–2071. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000003480>.

Dukát A, Filipová S, Gavorník P et al. Diabetes mellitus a hypertenzia – letálne duo. Forum Diab 2012; 1(1–2): 86–91.